Delivra Health Brands Inc.
Middle East Freeze Sparks Deep Value Discount
Published: June 17, 2026
Author: FRC Analysts
Disclosure: Delivra Health Brands Inc. has paid FRC a fee for research coverage and distribution of reports. See last page for other important disclosures, rating, and risk definitions.
Report Highlights
- Q3 Revenue Severely Impacted by Middle East Logistical Freeze: Revenue declined 60% YoY, missing our estimate by 29%, due to a sharp drop in Middle East sales as regional conflict and Strait of Hormuz disruptions caused distributors to suspend orders. Although ordering activity improved in Q4, we expect another weak quarter. These disruptions were not unique to Delivra and affected many multinational consumer product companies. We expect shipments to gradually normalize over the coming months as U.S.-Iran negotiations have advanced materially.
- Margin Squeeze Triggers Quarterly Loss: Gross margins fell sharply on lower sales volume, pushing EPS down YoY from ($0.01) to ($0.03), missing our $0.003 estimate, despite significant cuts to G&A and marketing expenses.
- Domestic E-Commerce Remains a Resilient Bright Spot: North American e-commerce sales provided a buffer, growing 22% YoY on average across all brands, signalling strong repeat customer engagement.
- Core Fundamentals Intact: We believe the company’s long-term fundamentals remain intact and that the distribution freeze is temporary, affecting only near-term revenue and EPS.
- LivRelief Brand Reactivation: DHB partnered with Peak Processing Solutions (ASX: PKP), an established cannabis products manufacturer and distributor in Canada, to license and relaunch its largely inactive LivRelief Infused™ line in Canada, generating a new revenue stream beginning Q4-FY2026.
- US Retail Expansion of Dream Water Kids: Following strong adoption of its adult line, DHB launched Dream Water Kids Sleep Gummies in March 2026, its first pediatric product. Studies indicate that 25–50% of US children experience chronic sleep issues. Unlike the adult line, the children’s formula contains a lower melatonin dose and child-focused ingredients. While the launch expands DHB’s addressable market, the pediatric sleep category is highly competitive and faces greater regulatory and consumer scrutiny than adult products.
- Undervalued Balance Sheet Limits Downside: Working capital net of long-term debt is $2.94M against a $3.13M MCAP, meaning the market values the core operating business at just $0.19M. The stock currently trades at just 0.24x forward revenue, representing a 79% discount to the industry peer average of 1.12x.
- Extremely Depressed Valuation Invites M&A: We are lowering our FY2026/FY2027 estimates but leaving FY2028+ intact. With the shares down 38% since our March 2026 report, we believe the current valuation may attract interest from larger players. Given the compelling risk/reward profile, we are adding DHB to our Top Picks list.
Price and Volume (1-year)
Quick insights from the CEO in our short interview
* Delivra Health has paid FRC a fee for research coverage and distribution of reports. All figures in C$ unless otherwise specified. See last page for other important disclosures, rating, and risk definitions.
To view the complete report, click on the button above
The opinions expressed in this report are the true opinions of the analyst(s) about any companies and industries mentioned. Any “forward looking statements” are our best estimates and opinions based upon information that is publicly available and that we believe to be correct, but we have not independently verified with respect to truth or correctness. There is no guarantee that our forecasts will materialize. Actual results will likely vary. The companies listed above are covered by FRC under an issuer-paid model, where fees have been paid to FRC to commission this report and research coverage. This creates a potential conflict of interest which readers should consider. Distribution procedure: our reports are distributed first to our web-based subscribers on the date shown on this report then made available to delayed access users through various other channels for a limited time. To subscribe for real-time access to research, visit https://www.researchfrc.com/plans for subscription options. This report contains “forward looking” statements. Forward-looking statements regarding the Company, industry, and/or stock’s performance inherently involve risks and uncertainties that could cause actual results to differ from such forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products/services in the marketplace; acceptance in the marketplace of the Company’s new product lines/services; competitive factors; new product/service introductions by others; technological changes; dependence on suppliers; systematic market risks and other risks discussed in the Company’s periodic report filings, including interim reports, annual reports, and annual information forms filed with the various securities regulators. By making these forward-looking statements, Fundamental Research Corp. and the analyst/author of this report undertakes no obligation to update these statements for revisions or changes after the date of this report. Fundamental Research Corp DOES NOT MAKE ANY WARRANTIES, EXPRESSED OR IMPLIED, AS TO RESULTS TO BE OBTAINED FROM USING THIS INFORMATION AND MAKES NO EXPRESS OR IMPLIED WARRANTIES OR FITNESS FOR A PARTICULAR USE. ANYONE USING THIS REPORT ASSUMES FULL RESPONSIBILITY FOR WHATEVER RESULTS THEY OBTAIN FROM WHATEVER USE THE INFORMATION WAS PUT TO. ALWAYS TALK TO YOUR FINANCIAL ADVISOR BEFORE YOU INVEST. WHETHER A STOCK SHOULD BE INCLUDED IN A PORTFOLIO DEPENDS ON ONE’S RISK TOLERANCE, OBJECTIVES, SITUATION, RETURN ON OTHER ASSETS, ETC. ONLY YOUR INVESTMENT ADVISOR WHO KNOWS YOUR UNIQUE CIRCUMSTANCES CAN MAKE A PROPER RECOMMENDATION AS TO THE MERIT OF ANY PARTICULAR SECURITY FOR INCLUSION IN YOUR PORTFOLIO. This REPORT is solely for informative purposes and is not a solicitation or an offer to buy or sell any security. It is not intended as being a complete description of the company, industry, securities or developments referred to in the material. Any forecasts contained in this report were independently prepared unless otherwise stated, and HAVE NOT BEEN endorsed by the Management of the company which is the subject of this report. Additional information is available upon request. THIS REPORT IS COPYRIGHT. YOU MAY NOT REDISTRIBUTE THIS REPORT WITHOUT OUR PERMISSION. Please give proper credit, including citing Fundamental Research Corp and/or the analyst, when quoting information from this report. The information contained in this report is intended to be viewed only in jurisdictions where it may be legally viewed and is not intended for use by any person or entity in any jurisdiction where such use would be contrary to local regulations or which would require any registration requirement within such jurisdiction.
